Especially the fact, that the mode-of-action of EnanDIM® molecules via TLR9 starts upstream of the targets of checkpoint inhibitors like anti-PD-1/anti-PD-L1 a combinatory approach may ideally be suited for a synergistic immune activation and thus enhanced anti-tumor effects. This evidence concerns the gene TLR9 and neoplasm.